瑞典评分阴道镜评估在瑞典筛查项目中的有效性评价:一项横断面研究
共纳入11317次评估,瑞典评分每增加一步CIN2+的比值比均升高,评分≥8时特异度93.3%、阳性预测值60.1%、AUC 0.71,细胞学与HPV联合AUC 0.88;作者认为瑞典评分在常规临床中表现良好但劣于既往临床研究,未确定安全避免活检的阈值。
要点
- 瑞典评分每增加一步,CIN2+的比值比均升高。
- 瑞典评分≥8时特异度93.3%、阳性预测值60.1%、AUC 0.71。
- 转诊细胞学异常时,瑞典评分0-1的CIN2+风险仍超过5%。
核心结论
- 瑞典评分在常规临床环境中表现良好,但阴道镜评估效果劣于既往临床研究报告。
- 未确定可安全避免活检的阈值。
- 仅当转诊细胞学显示高级别鳞状上皮内病变时,瑞典评分8-10的即查即治才可行。
研究设计与样本
- 共纳入11317次带瑞典评分的阴道镜评估。
- 将带瑞典评分的阴道镜与宫颈上皮内瘤变2级或以上(CIN2+)的组织病理诊断进行比较。
- 在回归模型中分析转诊时及阴道镜同时进行的细胞学和HPV检测对CIN2+的各自影响。
主要发现
- 瑞典评分每增加一步,CIN2+的比值比均升高。
- 瑞典评分≥0-1时,CIN2+的比例为9.8%。
- 瑞典评分≥8时,特异度为93.3%,阳性预测值为60.1%,受试者工作特征曲线下面积(AUC)为0.71。
- 若转诊时涂片异常,正常阴道镜(瑞典评分0-1)仍与超过5%的CIN2+风险相关。
- 回归模型中,细胞学和HPV对CIN2+的比值比高于阴道镜,两者联合的AUC为0.88。
关键数值与推荐
- 瑞典评分≥0-1时CIN2+比例为9.8%。
- 瑞典评分≥8时特异度93.3%、阳性预测值60.1%、AUC 0.71。
- 转诊细胞学异常时,瑞典评分0-1的CIN2+风险超过5%。
- 细胞学与HPV联合的AUC为0.88。
临床怎么用
- 作者认为瑞典评分在常规临床环境中表现良好。
- 作者认为仅当转诊细胞学显示高级别鳞状上皮内病变时,瑞典评分8-10的即查即治才可行。
- 作者指出未确定可安全避免活检的阈值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness and performance of Swedescore in the Swedish screening programme. DESIGN: Cross-sectional register study. SETTING AND POPULATION: All Swedish women aged over 18 years with a colposcopic assessment linked to a biopsy in the Swedish National Cervical Screening Registry, 2015-20. METHODS: Colposcopies with Swedescore were compared with the histopathological diagnosis of cervical intraepithelial neoplasia grade 2 or higher (CIN2+). The respective influence of cytology and human papillomavirus (HPV) testing, at referral for colposcopy and concurrently with colposcopy, were investigated in regression models. MAIN OUTCOME MEASURES: CIN2+. RESULTS: A total of 11 317 colposcopic assessments with Swedescore were included. Odds ratios for CIN2+ increased for every step in the Swedescore scale. At Swedescore ≥0-1, the proportion of CIN2+ was 9.8%. At Swedescore ≥8, the specificity was 93.3% and the positive predictive value was 60.1%, Area under the receiver operating characteristics curve (AUC) was 0.71. If the smear had been abnormal at referral, a normal colposcopy (Swedescore 0-1) was still associated with a CIN2+ risk of more than 5%. In the regression model, cytology and HPV had higher odds ratio for CIN2+ than colposcopy; the combination resulted in an AUC of 0.88. CONCLUSIONS: Swedescore works well in a routine clinical setting but colposcopy assessed with Swedescore was inferior to that reported in previous clinical studies. No safe cutoff level was identified for refraining from biopsy. See-and-treat at Swedescore 8-10 is feasible only if referral cytology showed high-grade squamous intraepithelial lesion. TWEETABLE ABSTRACT: No safe cutoff level for refraining from biopsy nor for see-and-treat with Swedescore.
引用
- Alfonzo E, Holmberg E, Milsom I, et al. Colposcopic assessment by Swedescore, evaluation of effectiveness in the Swedish screening programme: a cross-sectional study. BJOG. 2021. PMID: 34894043. doi:10.1111/1471-0528.17054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。